-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 10, the NMPA official website showed that Qilu Pharmaceutical's Decitabine for Injection and Cefminox Sodium for Injection passed the consistency evaluation.
Cefminox is a cephalosporin derivative, which belongs to the second generation of cephalosporins, which has the characteristics of broad antibacterial spectrum, strong bactericidal power, and multiple indications.
Decitabine is a specific inhibitor of deoxyribonucleic acid methylation.
Decitabine for injection is the fifth batch of varieties to be collected.
Up to now, Qilu Pharmaceutical has 68 varieties (121 product regulations) passed/deemed to have passed the consistency evaluation, of which 34 varieties are the first domestic ones to have passed the evaluation, and 21 varieties are injections.
Among the 60 varieties collected in the fifth batch, Qilu Pharmaceutical has 11 over-rated varieties selected, including oxaliplatin injection, isosorbide mononitrate sustained-release tablets, docetaxel injection, saxagliptin tablets, Fasudil Hydrochloride Injection, Palonosetron Hydrochloride Injection, Ceftriaxone Sodium for Injection, Ceftazidime for Injection, Gemcitabine Hydrochloride for Injection, Decitabine Hydrochloride for Injection and Ropivacaine Hydrochloride Injection.
Source: Mi Neiwang database, NMPA